Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Tax Provisions (2020 - 2022)

Historic Tax Provisions for Tarsus Pharmaceuticals (TARS) over the last 3 years, with Q3 2022 value amounting to -$5000.0.

  • Tarsus Pharmaceuticals' Tax Provisions rose 9853.37% to -$5000.0 in Q3 2022 from the same period last year, while for Jun 2023 it was -$5000.0, marking a year-over-year increase of 9825.17%. This contributed to the annual value of -$4000.0 for FY2022, which is 10727.27% down from last year.
  • According to the latest figures from Q3 2022, Tarsus Pharmaceuticals' Tax Provisions is -$5000.0, which was up 9853.37% from $1000.0 recorded in Q1 2022.
  • In the past 5 years, Tarsus Pharmaceuticals' Tax Provisions registered a high of $313000.0 during Q1 2021, and its lowest value of -$341000.0 during Q3 2021.
  • In the last 3 years, Tarsus Pharmaceuticals' Tax Provisions had a median value of $1000.0 in 2020 and averaged $7428.6.
  • Its Tax Provisions has fluctuated over the past 5 years, first plummeted by 3420000.0% in 2021, then surged by 9853.37% in 2022.
  • Quarter analysis of 3 years shows Tarsus Pharmaceuticals' Tax Provisions stood at $1000.0 in 2020, then soared by 5300.0% to $54000.0 in 2021, then tumbled by 109.26% to -$5000.0 in 2022.
  • Its Tax Provisions was -$5000.0 in Q3 2022, compared to $1000.0 in Q1 2022 and $54000.0 in Q4 2021.